Once again the President has been shown to be right. A new study conducted by the Henry Ford Health System found that those COVID-19 patients given hydroxychloroquine (HCQ) in a hospital setting were far less likely to die. The study covered 2,541 hospitalized patients.
CNN reported the “surprising” results. Dr. Marcus Zervos, division head of infectious disease for Henry Ford Health System, said,
“What we think was important in ours … is that patients were treated early. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with Covid.”
Dr. Steven Kalkanis, CEO of the Henry Ford Medical group, was careful not to put down some earlier “studies” that showed little or no benefit. Kalkanis noted,
“We also want to make the point that just because our results differ from some others that may have been published, it doesn’t make those studies wrong or definitely a conflict. What it simply means is that by looking at the nuanced data of which patients actually benefited and when, we might be able to further unlock the code of how this disease works.”
“Much more work needs to be done to elucidate what the final treatment plan should be for Covid-19. But we feel … that these are critically important results to add to the mix of how we move forward if there’s a second surge, and in relevant other parts of the world. Now we can help people combat this disease and to reduce the mortality rate.”
These results are hardly surprising. Multiple doctors have gone public with data that shows a clear benefit to the early use of HCQ in treating COVID-19. A study of more than 6,000 doctors around the world showed HCQ to be the drug of choice in combatting the infection. In all such public statements the emphasis was on early intervention with HCQ. Patients with infections that had progressed significantly were less likely to benefit.
It has been widely reported in this country that various healthcare workers on the frontline have been taking HCQ as a prophylactic. A study in India revealed that consumption of four or more maintenance doses of HCQ led to a significant decline in the odds of healthcare workers getting infected with the coronavirus infection. It appeared that workers taking HCQ were 80% less likely to become infected.
CNN, along with other anti-Trump media outlets, have been incurious about why countries in Asia have much lower death rates than Europe and America. If there was a treatment that the US has overlooked, one would think they would pounce on it to show how “incompetent” PDJT is. Howard Richman at American Thinker reports,
According to worldometers, only 3 people per million have died in China, 6 per million in South Korea, 8 per million in Japan and 14 per million in India. Compare that with 400 per million in the U.S.A, 537 in Sweden, 651 in U.K.
India’s The National Herald reports,
The combination noted here (HCQ, Z-Paks and zinc) were touted early during the pandemic by Dr. Zelenko in NY State. However, once PDJT mentioned HCQ as a promising treatment, the Democrats and their media outlets went into overdrive to create ungrounded fear in the treatment. Neil Cavuto over at Fox News went so far as to say on national TV “This drug will kill you.”
Beating the epidemic does not work well with the Democratic political calculations for winning the presidency in November. Conquering COVID-19 would mean that the economy would re-open sooner. And the Democrats cannot afford to have that happen. What appears to be a V-shaped recovery is already taking place. So they would rather have people die than be saved if those deaths advance their political agenda.
The American people need to remember this in November.